PBLS · Intrinsic value
Is Parabilis Medicines, Inc. (PBLS) overvalued or undervalued?
As of Oct 19, 2026, TickerWorth publishes a fair-value range of $8.80 – $8.80 for Parabilis Medicines, Inc. (PBLS), against the delayed market price of $25.95: priced above our range. It is a range, not a single number, so we do not call it over- or undervalued. It is a model estimate, and every input behind it is sourced below.
Model by Miraaj Patel · generated from market data · Updated Oct 19, 2026 · How these pages are made
What is PBLS worth?
- Fair-value range
- $8.80 – $8.80
- Market price
- $25.95
- Gap to fair value
- —
- Verdict
- Priced above our range
Reverse DCF: no growth rate up to 300%/yr justifies the price under these economics
What is PBLS's TickerWorth Score?
Scores lower than almost every company we compare it with
Compared with Healthcare companies in US
Its strongest point: looks cheap on the numbers. Its weakest: profitability is weak.
- Value · 69 of 100
Cheaper than 69% of Healthcare companies in US
- Price vs worth · 0 of 100
- Quality · 0 of 100
More profitable than almost none of the Healthcare companies in US
- Financial health · 67 of 100
Financially stronger than 67% of Healthcare companies in US
- Growth · — of 100
- Momentum · 27 of 100
Outperformed 27% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
Why PBLS gets a range, not one number
At a recent price of $25.95, Parabilis Medicines, Inc. (PBLS) sits above every lens we ran: our valuation lenses put the business somewhere between $8.80 and $8.80 per share. They disagree too widely for us to state a single fair value. We publish the range rather than a midpoint because a number that precise would claim more than the methods can support. This is an educational model, not a price target or a recommendation.
Read the full reasoning
The valuation discounts Parabilis Medicines, Inc.'s projected free cash flows at a weighted-average cost of capital (WACC) of 10.3%, with a long-run terminal growth rate of 2.5%. About 70% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, PBLS's modeled DCF value ranges from about $8.80 to $8.80 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what Parabilis Medicines, Inc. would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of PBLS's intrinsic value. Figures update as new filings and prices come in.
Every input behind PBLS's DCF
| Input | Value |
|---|---|
| Base-year revenueLive feed — totalRevenue (TTM) | $150,000 |
| Base EBIT marginComputed — trailing operatingMargins, held roughly flat | 2.0% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 5% → 5% → 4% → 4% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.2% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 1.10 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesLive feed — sharesOutstanding | 122M |
| Market priceDelayed quote · as of 2026-10-19 16:18 UTC | $25.95 |
Change PBLS's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does Parabilis Medicines, Inc. do?
What does it do?
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 145 people.
How does it make money?
The business turns $148,000 in annual revenue into profit. Out of every $100 of sales, about $0 is left as operating profit (operating margin of -34382.4%), after a 0% gross margin on the products/services it sells. After all costs, taxes and interest, 0.0% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: carries heavy debt (4.5× equity), comfortably covers its short-term bills (17.9× current ratio), and is currently lossmaking.
Who at PBLS filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Open-market buy | $1,406,632.50 | Form 4 for RA CAPITAL MANAGEMENT, L.P. (opens sec.gov in a new tab) | |
| RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Open-market buy | $606,620.16 | Form 4 for RA CAPITAL MANAGEMENT, L.P. (opens sec.gov in a new tab) | |
| RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Open-market buy | $189,721.68 | Form 4 for RA CAPITAL MANAGEMENT, L.P. (opens sec.gov in a new tab) | |
| RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Open-market buy | $1,131,690.00 | Form 4 for RA CAPITAL MANAGEMENT, L.P. (opens sec.gov in a new tab) | |
| RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Open-market buy | $2,670,487.29 | Form 4 for RA CAPITAL MANAGEMENT, L.P. (opens sec.gov in a new tab) | |
| RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Open-market buy | $914,399.64 | Form 4 for RA CAPITAL MANAGEMENT, L.P. (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Common questions
What is PBLS's intrinsic value?
TickerWorth's valuation lenses put Parabilis Medicines, Inc. (PBLS) between $8.80 and $8.80 per share, versus a market price of $25.95. They disagree too widely for us to state a single fair value, so we publish the range.
Is PBLS overvalued or undervalued?
At $25.95 the price sits above every lens we ran. We don't call PBLS overvalued or undervalued from a range this wide. This is an educational estimate, not advice.
What discount rate is used for PBLS?
A WACC of 10.3% and a terminal growth rate of 2.5%.
Is Parabilis Medicines stock undervalued?
TickerWorth's fair-value range for Parabilis Medicines, Inc. (PBLS) is $8.80 – $8.80 against a market price of $25.95. Priced above our range. We publish a range here, not one number, so we do not call it over- or undervalued. This is a model estimate, not investment advice.
Parabilis Medicines (PBLS) DCF valuation and fair value
Our fair-value range for Parabilis Medicines, Inc. (PBLS) is $8.80 – $8.80, built on a 10.3% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into Parabilis Medicines stock?
no growth rate up to 300%/yr justifies the price under these economics This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $25.95. A model estimate, not investment advice.
Parabilis Medicines (PBLS) insider trading
The most recent insider filing (SEC Form 4) for Parabilis Medicines, Inc. (PBLS): RA CAPITAL MANAGEMENT, L.P., Director, 10% owner, open-market buy on 2026-07-22. The latest filings are listed on this page. A disclosure, not a signal to trade.
Other ways into the coverage
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.